Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flotetuzumab first-in-human study in relapsed/refractory AML or high-risk MDS
NL-OMON55771Phase 2Completed
- Sponsor
- MacroGenics
- Start
- May 2017
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flotetuzumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by MacroGenics. Primary endpoint: CR/CRh rate. Started May 2017; status: completed.
02
Drugs
flotetuzumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON55771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55771.